Awareness Month, which seeks to raise recognition and push for research of this rare genomic imprinting disorder. PWS is estimated to affect about one in 20 000 individuals1 yet, until now, people ...

In a comprehensive Genomic Press Invited Expert Review, researchers from the University of Haifa have synthesized ...

The relentless hunger and associated behaviours significantly impact the quality of life for those with Prader-Willi syndrome ...

This figure illustrates the genomic structure of the PWS critical region on chromosome 15 ... have synthesized cutting-edge findings on Prader-Willi syndrome (PWS), revealing how this complex ...

Fourteen patients with the Prader-Willi syndrome and five suspected infants were studied cytogenetically. High-resolution chromosome analyses ... suspected infants. A 15;15 Robertsonian ...

In a comprehensive Genomic Press Invited Expert Review, researchers from the University of Haifa have synthesized ...

Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, according to a press release from Soleno Therapeutics.

The drug, to be called Vykat XR, treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder caused by full or partial deletions on chromosome 15 that affect the ...

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients. VYKAT XR is indicated for the treatment of hyperphagia in ...

Prader-Willi syndrome is a rare genetic disease that causes poor feeding in infancy but later triggers insatiable hunger.